Pharming (PHAR) Total Non-Current Liabilities (2019 - 2025)
Historic Total Non-Current Liabilities for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $121.2 million.
- Pharming's Total Non-Current Liabilities rose 112.11% to $121.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.2 million, marking a year-over-year increase of 112.11%. This contributed to the annual value of $105.1 million for FY2024, which is 3671.35% down from last year.
- As of Q3 2025, Pharming's Total Non-Current Liabilities stood at $121.2 million, which was up 112.11% from $118.8 million recorded in Q2 2025.
- In the past 5 years, Pharming's Total Non-Current Liabilities registered a high of $166.1 million during Q4 2023, and its lowest value of $135375.0 during Q3 2022.
- In the last 5 years, Pharming's Total Non-Current Liabilities had a median value of $121.2 million in 2025 and averaged $113.7 million.
- As far as peak fluctuations go, Pharming's Total Non-Current Liabilities crashed by 9991.57% in 2022, and later surged by 11695780.24% in 2023.
- Pharming's Total Non-Current Liabilities (Quarter) stood at $159098.9 in 2021, then soared by 101384.66% to $161.5 million in 2022, then rose by 2.88% to $166.1 million in 2023, then tumbled by 36.71% to $105.1 million in 2024, then increased by 15.32% to $121.2 million in 2025.
- Its Total Non-Current Liabilities was $121.2 million in Q3 2025, compared to $118.8 million in Q2 2025 and $110.4 million in Q1 2025.